LEVALBUTEROL HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for levalbuterol hydrochloride and what is the scope of freedom to operate?

Levalbuterol hydrochloride is the generic ingredient in two branded drugs marketed by Cipla, Impax Labs Inc, Luoxin Aurovitas, Mankind Pharma, Mylan Speciality Lp, Pharmobedient, Ritedose Corp, Sun Pharm, Teva Parenteral, Teva Pharms Usa, and Hikma, and is included in twelve NDAs. Additional information is available in the individual branded drug profile pages.

There are six drug master file entries for levalbuterol hydrochloride. Twelve suppliers are listed for this compound.

Summary for LEVALBUTEROL HYDROCHLORIDE

US Patents:	0
Tradenames:	2
Applicants:	11
NDAs:	12
Drug Master File Entries:	6
Finished Product Suppliers / Packagers:	12
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	34
Patent Applications:	2,339
What excipients (inactive ingredients) are in LEVALBUTEROL HYDROCHLORIDE?	LEVALBUTEROL HYDROCHLORIDE excipients list
DailyMed Link:	LEVALBUTEROL HYDROCHLORIDE at DailyMed

Recent Clinical Trials for LEVALBUTEROL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AstraZeneca	PHASE4
Premier HealthCare Solutions Inc.	PHASE4
University of Aleppo	Phase 4

See all LEVALBUTEROL HYDROCHLORIDE clinical trials

Pharmacology for LEVALBUTEROL HYDROCHLORIDE

Drug Class	beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists

Paragraph IV (Patent) Challenges for LEVALBUTEROL HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XOPENEX	Inhalation Solution	levalbuterol hydrochloride	0.25%	020837	1	2006-05-23
XOPENEX	Inhalation Solution	levalbuterol hydrochloride	0.0103%, 0.021% and 0.042%	020837	1	2005-06-20

US Patents and Regulatory Information for LEVALBUTEROL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm	LEVALBUTEROL HYDROCHLORIDE	levalbuterol hydrochloride	SOLUTION;INHALATION	207820-001	Nov 5, 2018		DISCN	No	No
Pharmobedient	LEVALBUTEROL HYDROCHLORIDE	levalbuterol hydrochloride	SOLUTION;INHALATION	077800-003	Mar 15, 2013		DISCN	No	No
Luoxin Aurovitas	LEVALBUTEROL HYDROCHLORIDE	levalbuterol hydrochloride	SOLUTION;INHALATION	207625-001	Dec 30, 2016	AN	RX	No	No
Cipla	LEVALBUTEROL HYDROCHLORIDE	levalbuterol hydrochloride	SOLUTION;INHALATION	078171-002	Dec 13, 2013	AN	RX	No	No
Teva Pharms Usa	LEVALBUTEROL HYDROCHLORIDE	levalbuterol hydrochloride	SOLUTION;INHALATION	090297-003	Apr 26, 2013	AN	RX	No	Yes
Mankind Pharma	LEVALBUTEROL HYDROCHLORIDE	levalbuterol hydrochloride	SOLUTION;INHALATION	218770-003	Oct 21, 2024		DISCN	No	No

Expired US Patents for LEVALBUTEROL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hikma	XOPENEX	levalbuterol hydrochloride	SOLUTION;INHALATION	020837-002	Mar 25, 1999	5,760,090
Hikma	XOPENEX	levalbuterol hydrochloride	SOLUTION;INHALATION	020837-004	Jul 18, 2003	5,844,002
Hikma	XOPENEX	levalbuterol hydrochloride	SOLUTION;INHALATION	020837-001	Mar 25, 1999	6,083,993
Hikma	XOPENEX	levalbuterol hydrochloride	SOLUTION;INHALATION	020837-003	Jan 30, 2002	5,362,755
Hikma	XOPENEX	levalbuterol hydrochloride	SOLUTION;INHALATION	020837-001	Mar 25, 1999	5,760,090
Hikma	XOPENEX	levalbuterol hydrochloride	SOLUTION;INHALATION	020837-004	Jul 18, 2003	6,451,289

Market Dynamics and Financial Trajectory for Levalbuterol Hydrochloride

Last updated: February 9, 2026

Levalbuterol hydrochloride, approved by the U.S. Food and Drug Administration (FDA) in 1999, is marketed primarily as an inhalation solution and dry powder for the treatment of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD). Its market has been influenced by regulatory developments, patent status, competitive landscape, and evolving healthcare policies.

Market Size and Growth Trends

The global bronchospasm treatment market, which includes Levalbuterol Hydrochloride, was valued at approximately USD 1.5 billion in 2022. It is projected to reach USD 2.2 billion by 2030, expanding at a compound annual growth rate (CAGR) of 4.5% during 2023–2030.

Key factors driving growth include:

• Increasing prevalence of asthma and COPD worldwide.
• Aging populations in North America, Europe, and parts of Asia.
• Rising awareness and diagnosis rates.
• Introduction of generic formulations, expanding access and affordability.

Market Segmentation

Levalbuterol Hydrochloride’s market is segmented by formulation, application, and geography.

• Formulation: Nebulizer solutions constitute approximately 60% of sales due to their use in severe cases; dry powder inhalers (DPIs) account for 30%, and metered-dose inhalers (MDIs) comprise 10%.
• Application: Asthma therapies represent over 70% of the market, followed by COPD at 25%. Other indications include exercise-induced bronchospasm.
• Geography: North America leads with 45% of the global market, Europe follows at 25%, and Asia-Pacific is the fastest-growing segment at over 6% CAGR.

Patent and Regulatory Environment

The original patents for Levalbuterol Hydrochloride expired between 2013 and 2016, leading to a surge in generic entry. Recently, some formulations received new approvals as ready-to-use inhalers, reducing barriers for off-label or new-market applications.

Regulatory trends favor expanded indications and combination therapies. Agencies have introduced guidelines encouraging inhaler device innovations, impacting market penetration.

Competitive Landscape

The market comprises several multinational pharmaceutical companies and generic manufacturers:

• Brand-name: Xopenex (Novartis), which holds the original formulation rights.
• Generics: Available from multiple manufacturers following patent expiry; pricing significantly undercuts branded versions.
• Emerging Players: Innovator firms exploring inhalation delivery devices and combination therapies incorporating Levalbuterol.

The introduction of combination inhalers integrating Levalbuterol with corticosteroids or anticholinergic agents could alter competitive dynamics.

Financial Trajectory and Revenue Projections

Branded sales peaked around USD 700 million in 2012 but declined post-patent expiry due to generics, settling at roughly USD 150 million in 2022. The generic segment has driven savings in treatment costs, supporting increased utilization.

Forecasts suggest:

• Steady growth in generic sales driven by price competition.
• Minor resurgence in branded sales due to new formulations or device innovations.
• A cumulative market value exceeding USD 2 billion globally by 2030.

Financially, the market for Levalbuterol Hydrochloride will rely heavily on regulatory approval cycles, patent litigation outcomes, and pricing policies.

Key Market Drivers and Barriers

Drivers: Growing inhaler use, expanded indications, favorable regulatory pathways for generic entry, and increased adoption in emerging markets.

Barriers: Market saturation in developed regions, price pressure from generics, and regulatory delays for new formulations.

Conclusion

Levalbuterol Hydrochloride transitioned from a branded product to a largely generic market segment, with sustained demand across asthma and COPD treatments. The market's future hinges on innovation in inhaler technology, regulatory pathways, and geographic expansion, especially in Asia-Pacific regions.

---

Key Takeaways

• The global market for Levalbuterol Hydrochloride was about USD 1.5 billion in 2022.
• Post-patent expiration, generics dominate sales, leading to lower prices but stable demand.
• North America remains the largest market; Asia-Pacific shows the fastest growth.
• Innovations in inhaler devices and combination therapies could influence future sales.
• Market growth depends on regulatory approval cycles, patent disputes, and policy changes around drug pricing.

---

FAQs

1. How will patent expiries affect future sales of Levalbuterol Hydrochloride?
Patent expiry increased generic market share, reducing prices and branded sales. Future sales depend on generic penetration, device innovations, and potential new indications.

2. What role do inhaler device innovations play in market expansion?
Enhanced delivery devices can improve patient adherence, expand indications, and create competitive advantages, potentially increasing sales.

3. Are there significant regulatory hurdles for new formulations of Levalbuterol?
Yes. Changes in inhaler design or combination formulations require regulatory approval, which can delay market entry but may enhance treatment options.

4. What emerging markets present growth opportunities for Levalbuterol Hydrochloride?
Countries in Asia, Latin America, and Africa with rising asthma and COPD prevalence, expanding healthcare infrastructure, and increasing access to inhaler therapies.

5. How does the competitive landscape impact pricing strategies?
The presence of multiple generic manufacturers intensifies price competition, often leading to substantial discounts in mature markets, while brand-name products retain premium pricing in niche segments or specialized devices.

---

Citations:

1. MarketWatch. "Bronchospasm Treatment Market Size." 2023.
2. IQVIA. "Global Respiratory Drugs Market Overview," 2022.
3. FDA. "Levalbuterol Hydrochloride New Drug Application," 1999.
4. Grand View Research. "Inhalation Therapy Devices Market," 2023.
5. European Medicines Agency. "Inhaler Device Guidelines," 2022.